Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition

Overview of attention for article published in Breast Cancer Research, April 2016

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 71 Dimensions

Readers on

mendeley: 62 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 71 publications that cite this research output.

71

The most recent citing publications are shown below. View all 71 publications that cite this research output on Dimensions.

PUMC-MB1 is a novel group 3 medulloblastoma preclinical model, sensitive to PI3K/mTOR dual inhibitor.

Article in Journal of Neuro-Oncology (April 2024)

A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation

Article in Molecular Cancer (March 2024)

Manipulating the tumor immune microenvironment to improve cancer immunotherapy: IGF1R, a promising target

Article in Frontiers in Immunology (February 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.